Ayvakit's label now lets some mastocytosis patients double the dose

The Food and Drug Administration approved a change to the Ayvakit label on 16 October that gives clinicians a lever they did not have before: for adults with indolent systemic mastocytosis, the dose may be raised from 25 mg once daily to 50 mg once daily after at least six months of treatment, as clinically indicated [s1][s2]. This is a dosing change, not a new disease — Ayvakit, made by Blueprint Medicines, has been approved for the condition since 2023 — but it is a meaningful one for a drug that had been fixed at a single low dose [s2].

Ayvakit is avapritinib, a tyrosine kinase inhibitor that targets KIT, the mutated signalling protein that drives the overgrowth of mast cells in systemic mastocytosis [s1]. Indolent systemic mastocytosis, or ISM, is the most common and least aggressive form: mast cells accumulate and release their contents, producing flushing, itching, abdominal pain, bone pain, brain fog and fatigue that can be severe even though the disease is not life-shortening in the way its advanced cousins are [s1].

What changed on the label

The starting dose stays at 25 mg once daily [s1]. What the supplement adds, in section 2.4, is the option to escalate to 50 mg once daily after six months if the response warrants it [s1]. The same approval also updated the drug-interaction and clinical-pharmacology sections to incorporate information about interactions with CYP3A substrates, alongside the existing instruction to avoid strong or moderate CYP3A inhibitors, which raise avapritinib levels [s1][s2].

The evidence behind the original dose

The 25 mg approval rested on PIONEER (NCT03731260), a randomised, double-blind, placebo-controlled trial in adults with ISM whose moderate-to-severe symptoms persisted despite at least two symptom-directed therapies [s1]. Patients took 25 mg of avapritinib or placebo, each on top of best supportive care, over a 24-week blinded period [s1].

The primary measure was the change in a patient-reported total symptom score. Scores fell by a mean of 15.33 points on avapritinib against 9.64 on placebo, a difference of 5.69 points (95% CI 1.23 to 10.16, p=0.012) [s1]. A quarter of patients on the drug — 25% — reached at least a 50% reduction in that score, against 10% on placebo (p=0.009) [s1]. The drug also lowered objective markers of mast-cell burden, including serum tryptase and the KIT D816V mutant allele fraction [s1].

What supports the higher dose

The case for 50 mg comes from the open-label extension of the same trial, where patients could keep taking avapritinib long term [s1]. Across the study, 226 patients received 25 mg once daily for a median of three years [s1]. Of those, 65 had their dose raised to 50 mg once daily — patients who had lost some disease control were eligible for the increase — and stayed on it for a median of about a year [s1]. The label reports that, based on observed data and pharmacokinetic-pharmacodynamic modelling, reductions in tryptase and in the KIT D816V allele fraction were seen after the increase to 50 mg [s1].

That is a narrower evidence base than a fresh randomised trial. The 50 mg option was not tested head-to-head against staying on 25 mg; the support is a single-arm extension in 65 patients. The honest reading is that the higher dose gives a route forward for people whose symptoms creep back, with biomarker movement to back it, rather than a demonstrated advantage over the starting dose for everyone.

What to watch

Avapritinib's label carries warnings that matter at any dose. The most serious is intracranial haemorrhage; the label advises patients to contact a provider immediately for neurological signs such as severe headache, vomiting, drowsiness, dizziness, confusion, slurred speech or paralysis [s1]. Cognitive effects are also flagged, with advice not to drive or operate machinery while affected, and the drug can cause photosensitivity and is hazardous in pregnancy [s1]. Whether doubling the dose shifts the frequency of these effects in routine use is the open question that only post-marketing experience will answer.

Red flags for anyone taking avapritinib: the neurological symptoms above warrant urgent care, and new or worsening confusion, memory or concentration problems should be reported to the treating team rather than managed alone.

This article describes an FDA labelling change and is not medical advice. Decisions about dose belong with the clinician managing the mastocytosis.